The financial burden of diagnosed bladder cancer is expected to grow between 2018 and 2028 in the seven major markets (7MM)* due to an increase in disease incident cases from over 225,000 to 275,000, at an annual growth rate (AGR) of 2.21%, says GlobalData, a leading data and analysis company.
The company’s latest report, ‘Bladder Cancer: Epidemiology Forecast to 2028’, notes that the US had the highest number of diagnosed incident and diagnosed prevalent cases of bladder cancer. In 2018, the US had over 76,000 diagnosed incident cases of bladder cancer and the number is expected to increase to more than 96,000 diagnosed incident cases by 2028 at an AGR of 2.58%. The increase in diagnosed incident cases may be due to changes in population and to steadily increasing incidence of bladder cancer in specific age groups.
Japan will see the largest increase of cases through the forecast period, at an AGR of 2.99%.
Nanthida Nanthavong, Epidemiologist at GlobalData, commented: “The most common risk factor of bladder cancer is tobacco use and cigarette smoking. However, smoking rates have decreased in the 7MM, including in Japan. A more convincing reason for the increase of cases is that the risk of developing bladder cancer increases with age. In the 7MM combined, the highest proportion of diagnosed incident cases of bladder cancer in 2018 was among the 70–79 years age group.”
* 7MM: The US, France, Germany, Italy, Spain, the UK and Japan
Information based on GlobalData’s report: ‘Bladder Cancer: Epidemiology Forecast to 2028’
